{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-23-000045","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.097014+00:00","generated_at":"2026-06-08T21:11:10.527916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials","bullets":["Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).","Cash, cash equivalents, and investments $144.3M at Sep 30, 2023; expected to fund operations into H1 2025.","BDTX-1535 Phase 1 expansion cohorts enrolling; initial NSCLC expansion data expected 2024; GBM dose escalation data later 2023.","BDTX-4933 Phase 1 trial dosed first patient; targeting KRAS, NRAS, BRAF mutations; dose escalation ongoing.","Mark Velleca appointed President and CEO in September 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-23-000045","json":"https://secwatch.observer/filing/0001701541-23-000045.json","markdown":"https://secwatch.observer/filing/0001701541-23-000045.md","text":"https://secwatch.observer/filing/0001701541-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/0001701541-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/bdtx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:11:10.527916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d71ba2bc6dd3db90b55c6c4fb11d6e53ad717f2","claim":"Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/0001701541-23-000045-index.htm","confidence":0.96,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}